No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
MRUS Merus
- 54.240
- -1.530-2.74%
Close Jun 18 16:00 ET
3.59BMarket Cap-19868P/E (TTM)
55.920High53.920Low681.15KVolume55.760Open55.770Pre Close37.25MTurnover1.28%Turnover RatioLossP/E (Static)66.24MShares61.61052wk High10.28P/B2.90BFloat Cap19.80552wk Low--Dividend TTM53.37MShs Float61.610Historical High--Div YieldTTM3.59%Amplitude7.255Historical Low54.680Avg Price1Lot Size
Pre-Market
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Merus Power Bags EUR20 Million Energy Storage Facility Contract in Finland
Merus Power (MERUS.HE) secured an order worth nearly 20 million euros from Swiss energy services provider Alpiq to build an energy storage facility in Valkeakoski, Finland. The Finnish company said We
Form 144 | Merus(MRUS.US) Officer Proposes to Sell 3.5 Million in Common Stocks
SEC FILLINGS DISCLOSED/ Jun 17, $Merus(MRUS.US)$ Officer Silverman Peter B. intends to sell 62,000 shares of its common stock on Jun 17, with a total market value of approximately $3.5 million. Sou
Stifel Maintains Merus(MRUS.US) With Buy Rating, Raises Target Price to $99
Stifel analyst Bradley Canino maintains $Merus(MRUS.US)$ with a buy rating, and adjusts the target price from $90 to $99.According to TipRanks data, the analyst has a success rate of 0.0% and a total
Merus Is Maintained at Buy by Stifel
Merus Is Maintained at Buy by Stifel
Express News | Merus NV : Stifel Raises Target Price to $99 From $90
Merus(MRUS.US) Officer Sells US$475.46K in Common Stock
$Merus(MRUS.US)$ Officer Shuman Harry sold 8,300 shares of common stock on Jun 10, 12, 2024 at an average price of $57.284 for a total value of $475.46K.Source: Announcement What is statement of chang
Comments
$SPDR S&P Biotech ETF(XBI.US$
$Merck & Co(MRK.US$ x $Immunovant(IMVT.US$
$Eli Lilly and Co(LLY.US$ x $Cytokinetics(CYTK.US$ (and soon)
$Regeneron Pharmaceuticals(REGN.US$ x $Apellis Pharmaceuticals(APLS.US$ (panache & brash)
$Gilead Sciences(GILD.US$ x % $Madrigal Pharmaceuticals(MDGL.US$ (liver king)
$Bristol-Myers Squibb(BMY.US$ x $Iovance Biotherapeutics(IOVA.US$ (cell Tx boost needed)
$Eli Lilly and Co(LLY.US$ x $Merus(MRUS.US$ (partner n...
$Merck & Co(MRK.US$ x $Immunovant(IMVT.US$
$Eli Lilly and Co(LLY.US$ x $Cytokinetics(CYTK.US$ (and soon)
$Regeneron Pharmaceuticals(REGN.US$ x $Apellis Pharmaceuticals(APLS.US$ (panache & brash)
$Gilead Sciences(GILD.US$ x % $Madrigal Pharmaceuticals(MDGL.US$ (liver king)
$Bristol-Myers Squibb(BMY.US$ x $Iovance Biotherapeutics(IOVA.US$ (cell Tx boost needed)
$Eli Lilly and Co(LLY.US$ x $Merus(MRUS.US$ (partner n...
3
Merus' high P/S ratio is worrisome due to underwhelming revenue forecasts. The company's declining revenue growth and below-industry growth predictions may cause a drop in the P/S ratio, risking shareholders' investments.
1
Following a turbulent period, there has been a notable change in the trajectory of biotech stocks. After experiencing significant downturns in 2021 and 2022, the $SPDR S&P Biotech ETF(XBI.US$ has seen an increase of 5.5% in the current year. However, it continues to trail considerably behind the $S&P 500 Index(.SPX.US$, which has achieved a 24% gain. However, analysts indicate that the previously cool sent...
28
1
$Merus(MRUS.US$ 71.55% is institutions owned, don't sell for cheap, at least 30.
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg